Compare Gap Inc (GAP) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Tango Therapeutics Inc. — how do they compare? Gap Inc trades at $22.66 (market cap $8.02B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Gap Inc is far larger — about 2.1× Tango Therapeutics Inc.'s market cap, and Gap Inc pays a 3.07% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Tango Therapeutics Inc. for 0 Days on average.
| GAP | TNGX | |
|---|---|---|
Market Cap | $8.02B | $3.75B |
Volume | 4,496,595 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $32.90 |
52-Week Low | $18.35 | $7.50 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | $11.25B | $2.77B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap trades at $22.67, down 0.48% on the day, with a bullish technical signal supported by strong moving averages. The company shows improving fundamentals with revenue growth to $15.09B in 2025 and net income margin expanding to 8.14%. Recent strategic moves include music partnerships and board appointments, while analyst consensus targets $25.67 with 31% buy ratings.
The outlook remains positive with projected 2026 revenue of $15.3B and net income of $1.2B, though risks include Old Navy's sales decline and competitive pressures. Valuation appears attractive with P/E of 6.88 and P/S of 0.56, suggesting potential upside to consensus targets if execution continues.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
